Ind-Swift Laboratories vs Sun Pharmaceutical Industries
Side-by-side stock comparison based on AI earnings call analysis
Which stock has stronger management signals?
Ind-Swift Laboratories currently has the stronger revenue growth signal.
Ind-Swift Laboratories show active capex signals based on earnings call analysis.
No strong fundraising signal is currently visible for either company.
| Metric | Ind-Swift Laboratories | Sun Pharmaceutical Industries |
|---|---|---|
| Current Price | ₹409.8 | ₹1,761 |
| Market Cap | ₹3,566.15 Cr. | ₹4.23 L Cr. |
| Industry | Pharmaceuticals & Biotechnology | Pharmaceuticals & Biotechnology |
| P/E Ratio | 54.78 | 33.46 |
| ROE (%) | 4.02 | 15.95 |
| Debt/Equity | 0.01 | 0.06 |
| Sales Growth 5Y (%) | -6.14 | 11.78 |
| Profit Growth 5Y (%) | 149.58 | 5.62 |
| Promoter Holding (%) | 42.93 | 52.68 |
| Revenue Rank | Rank 2 | Rank 3 |
| Margin Rank | Rank 3 | Rank 3 |
| Signal | — | — |
| Capex | Yes | No information |
| Fundraise | No information | No information |
Analyze Ind-Swift Laboratories →Analyze Sun Pharmaceutical Industries →Compare other stocks →Stock Screener →
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.